CIK 0001645113
- Large accelerated filer
NovoCure Ltd
Sign in to watch- Ticker
- NVCR
- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- FY end
- Dec 31
- Entity type
- Operating
- Phone
- +44 1534756700
- Business address
- NO. 4 THE FORUM, GRENVILLE STREET, ST. HELIER, Jersey
- 4 Open-market sale Chief Operating Officer sold 181 shares at $138.23 ($25,020)
- 4 Open-market sale Chief Commercial Officer sold 657 shares at an average $138.57 ($91,041)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Chief Financial Officer sold 26,624 shares at an average $140.94 ($3,752,286)
- 4 Derivatives Options or other derivatives
- 4 Open-market sale Director sold 34 shares at $153.13 ($5,206)
- 4 Open-market sale Chief Commercial Officer sold 2,063 shares at $148.71 ($306,789)
- 4 Open-market sale Director sold 1,000 shares at $152.50 ($152,500)
- 4 Open-market sale Chief Development Officer sold 1,041 shares at an average $149.39 ($155,520)
- 4 Open-market sale Chief Commercial Officer sold 1,654 shares at $149.43 ($247,157)
- 4 Open-market sale Executive Chairman sold 995 shares at $149.38 ($148,631)
- 4 Open-market sale Chief Medical Officer sold 464 shares at $150.11 ($69,651)
- 4 Open-market sale Chief Medical Officer sold 1,187 shares at an average $154.63 ($183,550)
- 4 Grant or award Chief Science Officer acquired 113 shares (grant or award)
- 4 Grant or award Chief Development Officer acquired 154 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 100 shares (grant or award)
- 4 Grant or award Chief Operating Officer acquired 66 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 90 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 118 shares (grant or award)
- 4 Grant or award Chief Commercial Officer acquired 154 shares (grant or award)
Page 14 of 39 · 780 filings